Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Custodio A, Carmona-Bayonas A, Villabona C, Perez M, de La Cruz G,
Keywords: neuroendocrine tumors, carcinoid syndrome, use of resources, costs,
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Martínez-Fuentes A
Authors: Díaz Pérez J, García-Carbonero R, Villabona C, Capdevila J, Jiménez-Fonseca P,
Keywords: sst4, RET, angiogenesis, GEP-NET,
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Teulé Vega A, Ochoa M, Villabona C, Cuadra C, Salazar Soler R,
Keywords: pancreatic neuroendocrine tumor, everolimus, octreotide LAR, case study,